MARINUS PHARMACEUTICALS INC's ticker is MRNS and the CUSIP is 56854Q101. A total of 4 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $2,591,000 | +36.5% | 1,020,012 | +9.1% | 0.00% | 0.0% |
| Q1 2020 | $1,898,000 | +64.9% | 935,088 | +75.5% | 0.00% | – |
| Q4 2019 | $1,151,000 | +30.6% | 532,964 | -6.9% | 0.00% | – |
| Q3 2019 | $881,000 | -61.3% | 572,265 | +4.3% | 0.00% | -100.0% |
| Q2 2019 | $2,276,000 | +1.2% | 548,467 | +1.9% | 0.00% | 0.0% |
| Q1 2019 | $2,250,000 | +96.0% | 538,263 | +34.6% | 0.00% | – |
| Q4 2018 | $1,148,000 | -71.4% | 399,908 | -0.4% | 0.00% | -100.0% |
| Q3 2018 | $4,017,000 | +46.8% | 401,709 | +3.8% | 0.00% | 0.0% |
| Q2 2018 | $2,736,000 | +1241.2% | 386,864 | +625.7% | 0.00% | – |
| Q1 2018 | $204,000 | -50.5% | 53,309 | +5.6% | 0.00% | – |
| Q4 2017 | $412,000 | +53.7% | 50,472 | +10.5% | 0.00% | – |
| Q3 2017 | $268,000 | +824.1% | 45,678 | +112.8% | 0.00% | – |
| Q2 2017 | $29,000 | -23.7% | 21,470 | 0.0% | 0.00% | – |
| Q1 2017 | $38,000 | +72.7% | 21,470 | 0.0% | 0.00% | – |
| Q4 2016 | $22,000 | -42.1% | 21,470 | +1.7% | 0.00% | – |
| Q3 2016 | $38,000 | +40.7% | 21,108 | 0.0% | 0.00% | – |
| Q2 2016 | $27,000 | -76.3% | 21,108 | 0.0% | 0.00% | – |
| Q1 2016 | $114,000 | -21.4% | 21,108 | +11.6% | 0.00% | – |
| Q4 2015 | $145,000 | – | 18,920 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 1,192,883 | $15,329,000 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 1,431,059 | $18,389,000 | 1.71% |
| Avoro Capital Advisors LLC | 3,000,000 | $38,550,000 | 0.55% |
| Palo Alto Investors LP | 31,330 | $403,000 | 0.02% |